2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses de-escalating treatments for patients with triple-negative breast cancer (TNBC).
Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses de-escalating treatments for patients with triple-negative breast cancer (TNBC).
In the de-escalating realm, the use of neoadjuvant therapy is beneficial for minimizing the need for surgery, explains Carey. Data from non-randomized studies suggest that very small node-negative TNBC may not have much of a benefit from chemotherapy.
According to Carey, one of the hopes is the possibility of minimizing the use of anthracyclines. However, current data and prospective studies show that they still play a role in TNBC.
Related Content: